Healthcare  Contact Us


There are many challenges facing healthcare, from aging populations, rapidly growing demand for health products and services, severe budget pressures and government reform to global health threats that defy conventional approaches. And each challenge requires the most imaginative of minds – people willing to ask big questions, take risks and tackle complex problems in new ways. At FleishmanHillard, we believe...

There are many challenges facing healthcare, from aging populations, rapidly growing demand for health products and services, severe budget pressures and government reform to global health threats that defy conventional approaches. And each challenge requires the most imaginative of minds – people willing to ask big questions, take risks and tackle complex problems in new ways. At FleishmanHillard, we believe there's an answer to every question that can be posed – we just have to be curious, persistent, collaborative and creative enough to find it. So regardless of the task – building brand loyalty, educating the public or defending a marketplace in the face of intense competition – our team provides the curiosity, experience and confidence to push the boundaries of healthcare communications.

What We Do

Reputation Management

Our teams provide a wide spectrum of reputation management consulting services, from support for leadership changes and mergers and acquisitions to employee communications, issues preparedness and crisis response. Equipped with proprietary tools such as our Authenticity Gap methodology, we help organizations across the healthcare sector identify and take positive steps toward managing the gaps between their brand and reputation.

Product Launch and Marketing

Each market and therapeutic category provides its own challenges, opportunities and circle of stakeholders. From clinical trial recruitment to end-of-lifecycle strategies, FleishmanHillard provides insights into the introduction and marketing of new and mature products. With a deep understanding of the regulatory environments and market complexities in which they work, our counselors have helped create powerful campaigns to launch products at a global, regional and national level – shaping a positive environment for product uptake and generating ongoing demand.

Clinical Trial Recruitment

FleishmanHillard provides specialized patient recruitment consulting for investigational pharmaceutical, biotechnology and medical device products. Working collaboratively with contract research organizations and our clients, we engage target populations through credible third-party sources – online and off – helping study sites raise awareness, educate and generate referrals.

Public Affairs and Government Relations

FleishmanHillard provides an in-depth understanding of local, regional and global healthcare issues, advocacy, alliance development, stakeholder engagement and government affairs. We help healthcare companies, trade associations and nongovernmental organizations navigate regulation, mobilize opinion leaders, and influence legislation and health policy. Our healthcare-focused public affairs experts around the world have extensive experience counseling organizations on the wide range of product, corporate and marketplace issues.

Digital and Social Outreach

FleishmanHillard’s digital and social experts worldwide help organizations apply new technologies, tools and channels to shape integrated communications programs that create a measurable impact. We work with clients to optimize the power of social media, including implementing policies for employees, launching branded promotional and unbranded educational campaigns, working with HR to enhance recruitment and retention, and coaching executives in the medium.


Animal healthcare
Health NGOs
Healthcare technology providers
Managed care and insurance providers
Medical equipment and device makers
Medical facilities and providers

Who We Are

  • From Stealthcare to Healthcare? A FleishmanHillard Policy Discussion

    Mark Senak

    June 23, 2017

    Mark Senak Since the enactment of the Affordable Care Act in 2009, there ensued a profound sense of déjà vu as Republican members of Congress tried to undermine the law through court challenges as well as through repeated attempts to vote a full repeal. Now in a majority in both the House and the Senate and with...

  • The FDA Welcomes A New Commissioner: What Will Dr. Gottlieb Do?

    Adam Silverstein

    May 18, 2017

    Adam Silverstein Mark Senak contributed to this article. Dr. Scott Gottlieb, the newly appointed commissioner of the U.S. Food and Drug Administration (FDA), has taken the lead of an agency that regulates one-fifth of the economy and oversees two of Americans’ most important commodities, food and medicine. As he gets to work, he’ll face a litany of issues...

  • New Year, New Administration, New FDA and New Cures: Approvals and Enforcement Outlook for 2017

    Mark Senak

    January 11, 2017

    Mark Senak Every U.S. federal agency is facing the potential for considerable change given a new Administration taking office this month, setting into motion the process whereby new heads of bureaucracies assume responsibility and bring different priorities and agendas to their respective roles. But one – the Food and Drug Administration – which regulates one-fifth of the...

  • These are Three Storylines We’re Watching at the J.P. Morgan Healthcare Conference

    Adam Silverstein

    January 5, 2017

    Adam Silverstein It’s that time of year again. We’re days away from the annual J.P. Morgan Healthcare Conference in San Francisco. All eyes will be on this gathering of the world’s biotechnology start-ups, pharmaceutical companies, medical device manufacturers, and health insurers. And it means that what company leaders say and the stories they tell media and investors,...

  • What's Next for 21st Century Cures Act?

    Mark Senak

    December 8, 2016

    Mark Senak The 21st Century Cures Act has been long in the making. First passed by the House of Representatives as in July 2015 by an overwhelming vote of 344 – 77, the bill hit the legislative wall in the Senate where, despite rumors of advancement over many months, it stayed put until after the election. Then,...

  • The Best of Cannes Lions Health: Smart Ideas, Well-Executed

    Heather Pierce

    June 20, 2016

    Heather Pierce The sheer volume of inspiring and excellent work shared at this year’s Cannes Lions Health has been remarkable—from breathtakingly beautiful films to stunning works of art and fantastically creative social campaigns. As I watched the awards ceremony presentations, I had two realizations. First, as health communicators we often get weighed down by our largely conservative...

  • Cannes Lions Health: Empathy Is the Key to Life-Changing Creativity

    Heather Pierce

    June 18, 2016

    Heather Pierce Earlier today at Cannes Lions Health, Genentech (a FleishmanHillard client) shared the powerful findings of their Lung Cancer Project, a study which sought to identify and understand unconscious bias. They found that an astonishing three out of four people had negative perceptions about lung cancer, which likely contributes to the high percentage of people diagnosed...

  • Why Media Coverage of Medical Research is Making John Oliver Mad, and What PR Pros Could Do to Help

    Adam Silverstein

    May 10, 2016

    Adam Silverstein You’ve seen the headlines. They appeared on your Facebook feed, your Twitter handle and your local news. You probably overheard someone mention one on your way to work. Maybe you’ve even seen these: “Swaddling May Be Linked to SIDS, New Research Analysis Suggests” “Eating Moderate Amounts of Chocolate Could Benefit Mom and Baby” “Drinking a...

  • Is It Enough to Mean Well? The Importance of Empathy

    Heather Pierce

    March 3, 2016

    Heather Pierce A few weeks ago, I was helping to lead a client message training session for an amazing group of female philanthropists. These women are leading incredible global health initiatives, from addressing gender-based violence in Honduras and Trinidad to transforming sanitation in Vietnam and detecting and treating cervical cancer in India. As we were discussing their...

  • Considerations for a New FDA Commissioner

    Mark Senak

    February 26, 2016

    Mark Senak The Senate, in an 89-4 vote, confirmed Dr. Robert Califf as the new Commissioner for the Food and Drug Administration, which oversees the regulation of about one-fourth of the U.S. economy. With several “Holds” put on the nomination by more than a few members, including Senators Manchin, Markey, Murkowski and Sanders the question was whether...

  • What a Difference a Year Makes: Three Observations from the JPM Healthcare Conference

    Adam Silverstein

    January 25, 2016

    Adam Silverstein Hotel room rates in San Francisco have resumed being just expensive, not uber-expensive. Union Square is crowded, not overflowing. Sports talk in bars and restaurants is more likely to be about real football – the Super Bowl, Monday morning quarterbacks, watching from the sidelines, dropping the ball – than borrowed football metaphors to describe business...

  • Five Things to Watch for at the J.P. Morgan Healthcare Conference

    Adam Silverstein

    January 12, 2016

    Adam Silverstein San Francisco’s population is swelling, but the rising wave of people, much like the bay at high tide, will ebb. The flow of people into the city, specifically Union Square, is an effect of the 34th Annual J.P. Morgan (JPM) Healthcare Conference (JPM is a FleishmanHillard client), happening this week in San Francisco as it...

  • What Really Scares Me This Halloween

    Fran Carpentier

    October 30, 2015

    Fran Carpentier Halloween’s calling, and my heart’s in the right place—for a person living with Type 1 diabetes, that is. You see, despite my compliance to carb-counting and almost hourly blood tests, I’ve deep-rooted affection for this holiday of camp and kitsch and candy. But just like Cinderella (my all-time favorite princess-in-waiting if not Halloween costume), I...

  • Can Technology Bridge the Gap Between Knowing and Doing?

    Heather Pierce

    October 14, 2015

    Heather Pierce Chronic disease prevention isn’t sexy. Its core tenets induce eye rolls with their basic simplicity: “Eat better. Exercise more.” Ugh, how boring. Isn’t there some pill I can take to stave off a heart attack or cancer? A one-time shot to make me diabetes-proof? Healthcare providers and public health professionals have long struggled with how...

  • Speaking of Health – How the 21st Century Cures Act Impacts Healthcare Communications

    Mark Senak

    July 10, 2015

    Mark Senak The pace of change in healthcare is breathtaking. There are new ways to treat, new ways to research, new ways to pay for care, new ways to access care and new ways to communicate about it. Yet, in too many ways, the way we, as a nation, regulate remains a 20th century model plagued by...

  • Social Media at ASCO: Weekend in Review

    Adam Silverstein

    June 1, 2015

    Adam Silverstein Day 4 at the American Society of Clinical Oncology (ASCO) conference in Chicago brings with it some weary attendees and followers. Hundreds of abstracts have been presented on a range of cancers and generated some large conversation volumes, both in McCormick Place and online. On Friday, we previewed three topics and trends we’re watching at the meeting....

  • Sweet Home Chicago: What We’ll Be Watching at ASCO

    Adam Silverstein

    May 29, 2015

    Adam Silverstein Chicago, get ready. You’re about to have a lot more doctors, business executives and journalists. Thousands of them are gathering in the Windy City for the annual American Society of Clinical Oncology (ASCO), one of the largest oncology meetings in the world. While the surge will be temporary, the research and insights shared by oncologists...

  • Are We Too Optimistic About Progress in Cancer?

    Adam Silverstein

    April 29, 2015

    Adam Silverstein A giddy smile has taken hold of the faces of many oncologists and cancer patients. They have good reason to grin, for three reasons: We could be on the way toward doing away with the cancer biopsy. Researchers reported that a “liquid biopsy” blood test that’s possible due to advanced genome sequencing can find tiny pieces of cancer DNA in...

  • The FH 2015 Social Health Survey: A Second Opinion From Dr. Digital

    Alyssa Marderstein

    April 20, 2015

    Alyssa Marderstein Melissa Solomon and Adam Silverstein contributed to this article. Survey finds over 50% of patients consult with Dr. Google or Facebook before or after a doctor’s visit Our Social Health survey of more than 500 people reveals some important patient behaviors. First, patients form an opinion about a treatment option before they step foot in...

  • The FleishmanHillard 2015 Social Health Survey

    Ephraim Cohen

    April 7, 2015

    Ephraim Cohen How people care for themselves and others using social and mobile media Which networks people use and how they use them differs greatly depending on age range as well as whether the person is looking for information about their own health or finding information as a caregiver to someone else. The charts below show the...

  • It’s the Most Wonderful Time of Year

    Adam Silverstein

    January 16, 2015

    Adam Silverstein It’s the most wonderful time of year. For healthcare, that is. This week in San Francisco, over 300 healthcare companies, both public and private, presented vision, business objectives, challenges and opportunities for 2015 at arguably the year’s largest meeting, the 33rd Annual J.P. Morgan (client) Healthcare Conference. Investors, media, healthcare professionals, even patient advocates swarmed...

  • Putting Ebola Into Context

    Pippa Galbraith

    October 17, 2014

    Pippa Galbraith Striking a delicate balance between communicating a healthcare threat and managing public perceptions “Rumours and panic are spreading faster than the virus,” said Dr Margaret Chan, director general of the World Health Organisation on Monday this week. In the same speech she called the Ebola outbreak “a crisis for international peace and security”. While the...

  • Lots Left Unanswered After FDA Social Guidance

    Mark Senak

    July 15, 2014

    Mark Senak For almost five years, the pharmaceutical industry has essentially held its collective breath waiting for guidelines from the U.S. Food and Drug Administration on how it should operate on social media and the Internet. Out of a public hearing held in 2009 with pharmaceutical companies and medical device makers, five pressing questions were posed by...

  • No Roar From Pharma at Cannes Lions Health

    Jenyne Engelhardt

    June 15, 2014

    Jenyne Engelhardt And the Grand Prix winner is…Well, turns out we’re going to have to wait until next year at least in the pharmaceutical category. The pharma jury at the inaugural Cannes Lions Health festival shocked the audience at the Palais des Festivals by opting not to award one, throwing down a challenge to clients and agencies...

  • Saving Lives Is a Creative Endeavour

    Orla Burke

    June 15, 2014

    Orla Burke What if mobile phones could detect cancer cells? Or an ultrasound was performed via television? How would these disruptive technologies impact healthcare models and how would communications adapt to help save lives? These were amongst some of the most provocative questions asked on day one at Lions Health. During a session entitled Creative Ideas and Innovators...

  • It's Pharma's Turn for a Little Sunshine — Get Sunscreen

    Mark Senak

    June 12, 2014

    Mark Senak Last April, as the Centers for Medicare & Medicaid (CMS) released information about individual physician payments from Medicare, there was a firestorm of media about the big bucks some doctors and medical specialties were raking in from the federal program. National and locals outlets piled on, some even posting multiple articles, and naming names of...

  • Curiosity, Creativity and Healthcare

    Anne de Schweinitz

    June 12, 2014

    Anne de Schweinitz Some might think that those of us who work in healthcare lack the creative instinct, that our analytical minds and the rules restricting marketing and communications in the industry squeeze out any room for real originality and inspiration. I disagree completely. When I was a kid my favorite topic in school was biology. I was...

Most Recent

  • From Stealthcare to Healthcare? A FleishmanHillard Policy Discussion

  • The FDA Welcomes A New Commissioner: What Will Dr. Gottlieb Do?

  • New Year, New Administration, New FDA and New Cures: Approvals and Enforcement Outlook for 2017

  • These are Three Storylines We’re Watching at the J.P. Morgan Healthcare Conference

  • What's Next for 21st Century Cures Act?

By Author

By Date